skip to the content
 

HER2检测的结果对于治疗方案的选择有重要指导意义

精确的检测，能够鉴别出更适合使用赫赛汀（曲妥珠单抗）进行治疗的患者

  • 研究表明，在所有乳腺癌患者中，约 20-25% 为HER2+. 6-10
  • 众多研究一致表明，HER2过度表达与更差的总生存、更差的化疗、激素治疗应答相关。 11,12
  • HER2过度表达在疾病进程中持续存在，并促进肿瘤的侵袭性生长。6,13,2

由于赫赛汀（曲妥珠单抗）能够为HER2+乳腺癌患者带来总生存期延长的显著临床获益，精确的检测所有乳腺癌患者的HER2状态是非常重要的。

  • 在NSABP-B-31质量控制研究中，对DFS的观察分析表明：
    • 总体而言，检测结果显示IHC3+及FISH+的患者接受赫赛汀（曲妥珠单抗）治疗能够获得更佳的DFS获益。
    • FISH及IHC检测结果不同的各亚组中，平均获益稍弱，但由于样本数量较少无法得出确定性结论。

 

 

HER2基因的过度复制导致细胞表面HER2蛋白的持续过度表达 2

 

References:

1. 赫赛汀（曲妥珠单抗）中文处方信息

2. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26 (suppl 12): 60-70.

3. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. JClin Oncol.2007;25:118-145.

4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med.2007;131:18-43.

5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1; 2007. Available at: http://www.nccn.org. Accessed February 21, 2007.

6. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone-receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.

7. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.

8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.

9. Pegram M, Slamon DJ. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;5(suppl 9):13-19.

10. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.

11. Paik S, Hazan R, Fischer ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.

12. Ross JS, Fletcher JA. HER2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(suppl 1):S53-S67.

13. Simon R, Nocito A, Hubscher T, et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 2001;93:1141-1146.

14. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002; 94:852-854.

15. O'Leary TJ. Standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2001; 9:3-8

16. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst. 2002;94:855-857.